



PHARMA OPEN INNOVATION SYMPOSIUM 2010



11TH ANNUAL DRUG DISCOVERY LEADERS SUMMIT

"Last year's meeting was absolutely superb" Vice President, Safety Evaluation & Risk Management, GSK

INTRODUCTION TO THE 2010 MEETING

Oxford Global Conferences is proud to present both the **11th Annual Drug Discovery Leaders Summit**, which is to be held on the 9th- 10th and its Pre-Conference Symposium on **Open Innovation** on the 8th June 2010 at Le Montreux Palace, Switzerland. The summit is the single most senior-level and focused event in Europe dedicated to the drug discovery and pharma market. This meeting will also be co-located with Oxford Global's **2nd Annual GPCR Congress**.

Over three days, the Summit will attract over 175 senior-level decision makers working in drug discovery from the UK, Europe and US's leading pharmaceutical, biotech, academic and research institutions. This prestigious event provides a forum for R&D and drug discovery practitioners and prominent innovators to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment.

THE SUMMIT & SYMPOSIUM

In keeping with Oxford Global's highly successful drug discovery series, an expert panel of speakers will present a full conference programme covering science, technology, strategy, data management and informatics, allowing attendees to gain an essential industry update. The symposium will be chaired by **Thomas Senderovitz**, Senior Vice President Global Development, Grunenthal. Key topics include:

OPEN INNOVATION SYMPOSIUM – 8th June 2010

Defining Open Innovation, Business Models, IP and Collaboration Issues, Academia Open Innovation, Biopharma Open Innovation, Current Open Innovation Initiative and Case Studies

DRUG DISCOVERY SUMMIT – 9th-10th June 2010

R&D STRATEGIES & BUSINESS MODELS AND PHARMA/BIOTECH ALLIANCES COLLABORATIONS –Challenges and strategies to enhance productivity in drug discovery such as open innovation, innovative business models, lean thinking and the benefits of industry and academic alliances

MEDICINAL CHEMISTRY / DRUG DESIGN – Reducing attrition in development, fragment based techniques, flow chemistry, reducing risk of toxicity, structure based discovery as well as hit to lead strategies

SCREENING TECHNIQUES & ASSAY DEVELOPMENT – Improving quality of assays, compound selection, target selection and validation, as well as cost effective lead identification Initiatives for HTS, HCS and label free as well as the potential of pluripotent stem cells

BIOMARKERS & PERSONALISED / TRANSLATIONAL MEDICINE –Translational medicine and diagnostic case studies as well as how Biomarkers facilitate early decision making in early development

BIOINFORMATICS – In-silico data, predictive modelling, Systems Biology

BIOLOGICS – Strategies to integrate biologics into an organisation, including presentations in phage display in peptides, a panel discussion on biobetters, case study on pepducins

WHO ATTENDS?

Delegates are pre-qualified dependent on budget, responsibility and seniority. Delegates are senior-level decision makers, from major pharmaceutical and biotech companies based in Europe and typically include SVPs, VPs and Directors of:

Drug Discovery	Biomarkers	Medicinal Chemistry	Screening	Strategic Alliances
R&D	Screening	Enabling Technologies	Genomics	Enabling Science
Toxicology	Proteomics	Structural Biology	Bioinformatics	Assay Development
Systems Biology	Translational Medicine	Lead Generation/ Validation/ Optimisation	Biologics	
Open Innovation	Technology Transfer	External Research	Business Strategy	
Technology Scouting	Business Development	Strategic Alliances	Strategy & Planning	

YOUR NETWORKING OPPORTUNITIES

Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities. Using our online appointment system, you are able to view the full profiles of all solution providers before the event. In addition you have the chance to pre-arrange one-to-one meetings with them, giving you the opportunity to discuss technologies, services and solutions that address your key business needs. Categories of solution providers include:

Biomarkers	Imaging	Strategy & Planning	Pre Clinical Analytical Testing
HTS / HCS	RNAi	Protein Sequencing	Microarray Technology
Proteomics	Genomics	Emerging Technologies	Data Management

Open Innovation Symposium - Confirmed Speakers 2010

- Thomas Senderovitz, Senior Vice President Global Development, Grunenthal
- Philip Oliver, Associate Director for Global External R&D Europe, Eli Lilly
- Giuseppe Ciaramella, Executive Director, Head of Biotherapeutics, Sandwich, Pfizer
- Chas Bountra, Chief Scientist, University of Oxford, Structural Genomics Consortium
- Peter Luke, Senior Director, Worldwide Business Development (Strategic Alliances), Pfizer
- Patrice Talaga, Director, Chemistry Outsourcing, UCB
- Jason Swedlow, Professor of Quantitative Cell Biology Wellcome Trust Centre for Gene Regulation & Expression, College of Life Sciences, University of Dundee
- Rob Cooke, Director, Science Environment Development, GSK

Drug Discovery Summit - Confirmed Speakers 2010

- Andrew von Eschenbach, Senior Advisor, Greenleaf Health
- Michel Pairet, Corporate Senior Vice President, Research, Boehringer Ingelheim
- Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GlaxoSmithKline
- Stephen Friend, President, CEO and a Co-Founder, Sage Bionetworks
- Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen
- Nick Terrett, Chief Scientific Officer, Ensemble Discovery Corporation
- Søren Bregenholt, COO, Symphogen
- Rob Hayes, CSO, CENTYREX a J&J Internal Venture
- Steve Hunt III, Senior Vice President, Discovery Research, Ascent Therapeutics
- John Desjarlais, Vice President, Research, Xencor
- Andrew Hopkins, Research Professor of Translational Biology & Chair of Medicinal Informatics Division of Biological Chemistry and Drug Discovery College of Life Sciences University of Dundee
- Jeremy Everett, Vice President, Research Centres of Emphasis, Sandwich, Pfizer
- Ben Askew, Vice President Research, Head of NCE Technologies, EMD Serono Research Institute
- Jutta Heim, Chief Technology Officer, Evolva SA
- Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, Head of Strategic Modeling and Simulation, Bristol Myers Squibb
- Karyn O'Neil, CSO, Johnson & Johnson Ventures
- Andreas Sewing, Research Fellow / Director, Primary Pharmacology Unit, Pfizer
- Salvatore Alesci, Senior Director & Head, Translational Immunology, Pfizer
- John Overington, Team Leader, Chemogenomics, EMBL – European Bioinformatics Institute, EMBL-EBI
- Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer
- Craig Johnstone, Value Chain Leader, RA-CVGI, AstraZeneca
- Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson
- Marjoleen Nijssen, Head Preclinical PK/PD, Abbott GmbH & Co. KG, Germany
- Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative Technology Centre, Department of Chemistry, Cambridge University
- Birgit Schoeberl, Vice President of Discovery, Merrimack Pharmaceuticals
- Paul Wyatt, Director of Drug Discovery, Division of Biological Chemistry & Drug Discovery, College of Life Sciences, University of Dundee
- Jin Li, Director of Computational Chemistry, AstraZeneca
- Jürgen Moll, Director, Dep. Cell Biology, Oncology, Nerviano Medical Sciences
- David J. Heard, Group Head Bioinformatics in Investigative Toxicology, Preclinical Safety, Novartis Institutes for Biomedical Research
- John Burke, Associate Director, Systems Biology, Biotherapeutics and Integrative Biology, Boehringer Ingelheim Pharmaceuticals
- Michael Braxenthaler, External Liaison Officer, The Pistoia Alliance & Global Head Strategic Partnerships and Sourcing Pharma Research Scientific Informatics (PRI) F. Hoffmann-La Roche Inc
- Niklas Blomberg, Associate Director, Computational Chemistry, AstraZeneca
- Jeffrey Waring, Associate Research Fellow, Senior Group Leader, Neuroscience Biomarker Discovery, Abbott
- Didier Pez, Team Leader Medicinal Chemistry, AB Science
- Ge Li, Chairman and CEO, WuxiApptec
- Alastair Lawson, Senior Director of Structural Biology, UCB
- Didier Pez, Team Leader Medicinal Chemistry, AB Science
- Jean-François Mayaux, Global Leader, Biotherapeutics & Protein Sciences, Sanofi Aventis
- Andy Davis, Associate Director, Physical & Metabolic Sciences, AstraZeneca
- Hans Winkler, Senior Director, Global Head Oncology Biomarkers, Ortho Biotech - Johnson & Johnson
- Anthony Davies, HCA Research Facility Manager, Trinity College Dublin
- Troels Koch, Vice President & CTO, Santaris Pharma A/S
- Andrea Cavalli, Senior Scientist, Computational Chemistry, Department of Drug Discovery and Development, Italian Institute of Technology, Genoa
- Maria Miteva, Senior Scientist, Molécules Thérapeutiques in silico (MTi) Université Paris
- Senior Representative Accelrys

Reserved Speakers 2010

- Viswanan Devanarayan, Director Statistical Science, Abbott
- Terence Barnhart, Senior Director Strategy and Continuous Improvement at Pfizer Global R&D
- Richardus Vonk, Senior Director, Head of Global Drug Discovery Statistics, BayerHealthcare
- Orest Hurko, Assistant Vice President Discovery Translational Research, Pfizer
- Josef Ozer, Senior Principle Scientist, Pfizer
- Dennis Smith, Academic Research Fellow, Pfizer
- Andrew W. Thomas, Group Leader, Medicinal Chemistry, F. Hoffmann La Roche
- Chiara Ghiron, Head of Department - Screening & Technologies, Siena Biotech

Pharma Open Innovation Symposium

8th June Le Montreux Palace, Switzerland

09.30 – 10.00	REGISTRATION & MORNING COFFEE
10.00 – 10.05	Welcome Speech Oxford Global
10.05 – 10.10	Symposium Chair Welcome Speech - Thomas Senderovitz, Vice President Global Exploratory Development, UCB New Medicines
10.10 – 10.35	<p>Why Open Innovation is a Key factor for Changing the Pharmaceutical R&D Model</p> <p>CONFIRMED: Thomas Senderovitz, Senior Vice President Global Development, Grunenthal</p>
10.35 – 11.00	<p>Panel / Roundtable Discussion - Defining Open Innovation and the Critical importance of Open Innovation to the Pharmaceutical Sector</p> <ul style="list-style-type: none"> • IP and Collaboration Issues <p>RESERVED: Stephen Friend, President, CEO and a Co-Founder, Sage Bionetworks All speaker invited to join</p>
11.00 – 11.25	<p>FIPNET: An Open Innovation Journey</p> <ul style="list-style-type: none"> • The continuing evolution of Lilly's FIPNET philosophy • Examples of specific initiatives • How the initiatives work in practice.....and results • Developing initiatives....work in progress <p>CONFIRMED: Philip Oliver, Associate Director for Global External R&D Europe, Eli Lilly</p>
11.25 – 11.55	MORNING REFRESHMENTS
11.55 – 12.20	<p>Current OI Initiative Case Studies – Pfizer Case Study</p> <p>CONFIRMED: Giuseppe Ciaramella, Executive Director, Head of Biotherapeutics, Sandwich, Pfizer</p>
12.20 – 12.45	<p>Embracing Open Innovation in Pharma</p> <ul style="list-style-type: none"> • The challenges facing big Pharma, and how the balance between internal and external R&D is changing • New opportunities arising for open innovation and how it can address some of the Pharma challenges • GSK's experiences with open innovation • Measuring the value of partnerships • New ventures sponsored by GSK in the field of open innovation <p>CONFIRMED: Rob Cooke, Director, Science Environment Development, GSK</p>
12.45 – 13.10	<p>Current OI Initiative Case Studies – Structural Genomics Consortium A No IP Policy Can Facilitate Science and Target Discovery"</p> <ul style="list-style-type: none"> • Examples of many large pharma working together pre-competitively • Tackling the biggest challenge in Drug Discovery requires pooling of academic and pharma skillsets and strengths • Accessing global talent pool to generate data quickly <p>CONFIRMED: Chas Bountra, Chief Scientist, University of Oxford, Structural Genomics Consortium</p>
13.10 – 13.35	<p>The Future of Pharma R&D: Somewhere Between Open and Reverse Innovation?</p> <ul style="list-style-type: none"> • Pharma R&D's productivity is declining and will not be sufficient to drive the future growth of industry • New business models are urgently needed to increase productivity and innovation of our pipelines • Pharma Open Innovation: what is it actually? • Innovation and future of Pharma business: Open and/or Reverse? <p>CONFIRMED: Patrice Talaga, Director Chemistry Outsourcing, UCB</p>
13.35 – 14.30	LUNCH

14.30 – 14.55	<p>The Open Microscopy Environment: Informatics and Quantitative Analysis for Biological Microscopy and HCAs</p> <p>The Open Microscopy Environment (OME) is a multi-site collaborative effort among academic laboratories and a number of commercial entities that produces open tools to support data visualization, management, and analysis for biological light microscopy and high content screening (HCS). Designed to interact with existing commercial software, all OME formats and software are free, and all OME source code is available under GNU public "copyleft" licenses. With a strong foundation for biological light microscopy in place, OME has begun extending its coverage to other fields of biological imaging. We have successfully developed a data model for HCS data, and are currently releasing preview versions of software for HCS data management and analysis, with full releases scheduled for June 2010. In collaboration with the EM Data Bank, we have begun modifying the OME Data Model to cover single particle electron microscopy.</p> <p>CONFIRMED: Jason Swedlow, Professor of Quantitative Cell Biology Wellcome Trust Centre for Gene Regulation & Expression, College of Life Sciences, University of Dundee</p>
14.55 – 15.20	<p>Pfizer Case Study – Title to be Confirmed</p> <p>RESERVED: Peter Luke Senior Director, Worldwide Business Development (Strategic Alliances), Pfizer</p>
15.20 – 15.45	<p>Lessons Learned from OI outside of Pharma - Case Study</p> <p>Invitation to: Hans Hofstrat, Vice President, Philips Research</p>
15.45 – 16.10	<p>Lessons learned from OI outside of Pharma</p> <p>Invitation to: Case Study from Nokia or HP</p>
16.10 – 16.35	<p>Closing Panel Discussion – Future of Open Innovation in the Pharmaceutical Sector</p> <p>RESERVED: All speaker invited to join</p>
16.35	End of Symposium and Afternoon Refreshments


11th Annual Drug Discovery Leaders Summit

9th – 10th June 2010, Montreux Palace, Switzerland

www.drugdiscovery-summit.com

Day 1 - Wednesday 9th June 2010

07.45 - 08.20	REGISTRATION & COFFEE – LEMAN
08.20 – 08.25	CONFERENCE ROOM 1: Leman A - R&D STRATEGIES Oxford Global Opening Address
08.25 – 08.30	Stream Chair Henrik Konarkowski, Vice President Strategic Alliances, Chemdiv. Inc
08.30 – 09.10	<p>Evolving from Drugs and Devices to Integrated Solutions: The Role of Regulation</p> <p>CONFIRMED: Andrew von Eschenbach, Senior Advisor, Greenleaf Health</p>
09.10 – 09.50	<p>Putting Biopharmaceuticals on the GlaxoSmithKline Map</p> <ul style="list-style-type: none"> • Diversifying for success • Small is beautiful? • Building world-class capabilities <p>CONFIRMED: Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GlaxoSmithKline</p>
09.50 – 10.30	<p>The Art of Target Selection</p> <p>CONFIRMED: Michel Pairet, Corporate Senior Vice President, Research, Boehringer Ingelheim</p>
10.30 – 11.00	MORNING REFRESHMENTS IN LA COUPOLE

	CONFERENCE ROOM 1: R&D STRATEGIES & BUSINESS MODELS AND ALLIANCES, COLLABORATIONS AND OUTSOURCING	CONFERENCE ROOM 2: DRUG DESIGN / MEDICINAL CHEMISTRY	CONFERENCE ROOM 3: SCREENING TECHNIQUES, ASSAY DEVELOPMENT & ENABLING TECHNOLOGIES
	Stream Chair –	Stream Chair –	Stream Chair – Senior Representative GE Healthcare
11.00 – 11.30	<p>Solution Provider Presentation</p> <p>Sponsored by Accelrys</p> 	<p>Solution Provider Presentation</p> <p>For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk</p>	<p>Solution Provider Presentation</p> <p>Sponsored by GE Healthcare</p>
11.30 – 12.00	<p>Solution Provider Presentation</p> <p>For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk</p>	<p>Solution Provider Presentation</p> <p>For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk</p>	<p>Solution Provider Presentation</p> <p>For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk</p>
12.00 – 12.30	<p>STREAM KEYNOTE PRESENTATION Sage: Together Building Probabilistic Causal Disease Models Via an Open Access Contributor Network</p> <p>CONFIRMED: Stephen Friend, President, CEO and a Co-Founder, Sage Bionetworks</p>	<p>STREAM KEYNOTE PRESENTATION A New Hit Identification and Screening File Strategy for Pfizer</p> <ul style="list-style-type: none"> • A new flexible strategy for hit identification • Sculpting the Pfizer screening file to improve efficiency and effectiveness • Innovative new approaches to file redundancy and attractiveness • Putting the strategy into practice <p>CONFIRMED: Jeremy Everett, VP, Special Operations, Worldwide Research Centres of Emphasis, Pfizer</p>	<p>STREAM KEYNOTE PRESENTATION Title to be Confirmed</p> <p>CONFIRMED: Andreas Sewing, Research Fellow / Director, Primary Pharmacology Unit, Pfizer</p>
12.30 – 13.30	LUNCH ON THE TERRASSE PETIT PALAIS		
13.30 – 14.00	<p>The Pistoia Alliance, an Industry-Driven Alliance to Streamline Pre-Competitive Information Flow in Life Sciences R&D</p> <p>CONFIRMED: Michael Braxenthaler, External Liaison Officer The Pistoia Alliance & Global Head Strategic Partnerships and Sourcing Pharma Research Scientific Informatics (PRI) F. Hoffmann-La Roche Inc</p>	<p>Title to be Confirmed</p> <p>CONFIRMED: Ben Askew, Vice President Research, Head of NCE Technologies, EMD Serono Research Institute</p>	<p>Driving the Enhancement and Exploitation of a Screening Compound Collection</p> <ul style="list-style-type: none"> • What makes an effective screening collection • Chemistry strategy to drive the improvement • Impact on lead generation • Need for innovation <p>CONFIRMED: Jin Li, Director, Computational Chemistry, AstraZeneca</p>
14.00 – 16.20	ONE TO ONE MEETINGS X 7 IN LEMAN A MEETING ROOM		

<p>16.20 – 16.50</p>	<p>Panel Discussion – Lean Thinking</p> <p>CONFIRMED: Panel Chair: Craig Johnstone, Value Chain Leader, RA-CVGI, AstraZeneca Ge Li, Chairman and CEO, WuxiApptec Andreas Sewing, Research Fellow / Director, Primary Pharmacology Unit, Pfizer</p> <p>RESERVED: Terence Barnhart, Senior Director Strategy and Continuous Improvement at Pfizer Global R&D</p>	<p>Panel Discussion – Computational Drug Discovery</p> <p>CONFIRMED: Andrea Cavalli, Senior Scientist, Computational Chemistry, Department of Drug Discovery and Development, Italian Institute of Technology, Genoa Niklas Blomberg, Associate Director, Computational Chemistry, AstraZeneca Didier Pez, Team Leader Medicinal Chemistry, AB Science</p> <p>RESERVED: Andrew W. Thomas, Group Leader, Medicinal Chemistry, F. Hoffmann La Roche</p>	<p>Panel Discussion – Classical HTS Versus "Disruptive Technologies"</p> <p>CONFIRMED: Panel Chair: Jutta Heim, Chief Technology Officer Evolva SA</p> <p>RESERVED: Chiara Ghiron, Head of Department - Screening & Technologies, Siena Biotech</p> <p>Invitation to: Senior Representative x3</p>
<p>16.50 – 17.20 17.20 – 17.50</p>	<p>AFTERNOON REFRESHMENTS IN LA COUPOLE</p> <p>Target Identification and Validation in Oncology: Are Good Targets the Bottleneck in Drug Discovery?</p> <ul style="list-style-type: none"> • The criteria: what are the criteria for a "good" target" in Oncology? • The strategies: what are the different target identification strategies? • The timing: when to start TV, how much is sufficient and when to stop? • The technologies: what are the preferred tools for TI/TV ? • The future: platform approaches and the impact of the human cancer genome initiatives <p>CONFIRMED: Jürgen Moll, Director, Dep. Cell Biology Oncology, Nerviano Medical Sciences</p>	<p>Can We Automate Drug Design?</p> <p>CONFIRMED: Andrew Hopkins, Research Professor of Translational Biology & Chair of Medicinal Informatics Division of Biological Chemistry and Drug Discovery College of Life Sciences University of Dundee</p>	<p>Miniaturisation of Cell based Assays for High Content Screening Problems and Solutions</p> <ul style="list-style-type: none"> • Over the last decade there has been a huge increase in the production and testing of new biologically active compounds against an ever-increasing range of therapeutic targets. • Cell based assays and High content screening technologies are becoming increasingly used within pre-clinical drug discovery programs. • With the advent of micron resolution robotics and nano litre capable liquid handlers, large scale and automated assay miniaturisation is now possible. The advantages of miniaturisation are clear, when one considers the savings in reagents and experimental materials. • In this presentation we will be covering a variety assay miniaturisation approaches specifically aimed at high content analysis. We will also be showcasing a novel environmental control technology developed by us at Trinity College, which offers the possibility of reducing assay sizes to volumes as small as 10nl <p>CONFIRMED: Anthony Davies, Director High Content Research Facility Trinity College Dublin</p>

17.50 – 18.20	<p>Drug Discovery in an Academic Setting; New Targets Some Novel, Some Recycled</p> <p>There are significant opportunities for university based drug discovery centres to generate value to patients, provided they do not compete with or merely replicate BioPharma. These centres need to find ways of developing activities complementary to the BioPharma industry, such as partially de-risking novel drug discovery targets, or tackling neglected and orphan diseases, whose patient base demographics or numbers are not suitable to generate sufficient income to offset the cost of drug development in a commercial setting.</p> <p>The talk describes the Drug Discovery Unit and how it is seeking to translate novel biology into new targets for drug discovery, and reposition targets with a history of drug discovery into the neglected diseases arena.</p> <p>CONFIRMED: Paul Wyatt, Director of Drug Discovery, Division of Biological Chemistry & Drug Discovery, College of Life Sciences, University of Dundee</p>	<p>Flow Chemistry (Title to be Confirmed)</p> <p>CONFIRMED: Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative Technology Centre, Department of Chemistry, Cambridge University</p>	<p>Locked Nucleic Acid: A Drug Discovery Platform - Enabling Novel Treatment Modalities</p> <ul style="list-style-type: none"> • There is great therapeutic potential in the silencing of coding and non-coding RNA • Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug discovery platform is a direct approach to realize the potential of RNA silencing • Santaris Pharma, and our partners, have used LNA to bring more than 10 drugs in pre-clinical and clinical development • In the presentation the essentials of the LNA drug discovery platform will be outlined, and our most advanced drug candidate, that represents a new modality for HCV treatment, will be presented. <p>CONFIRMED: Troels Koch, Vice President & CTO, Santaris Pharma A/S</p>
18.20 – 18.50	<p>Title to be Confirmed</p> <p>Invitation to:</p>	<p>Medicinal Chemistry Challenges for 21st Century Drug Discovery</p> <ul style="list-style-type: none"> • New strategies in medicinal chemistry to tackle attrition and design molecules with improved likelihood of survival • Chemical biology approaches for the identification and validation of new drug targets with high confidence in rationale • The opportunity for medicinal chemistry to contribute to drug design beyond the small molecule world <p>CONFIRMED: Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer</p>	<p>Potential of Induced Pluripotent Stem Cells for Drug Discovery</p> <p>Invitation to:</p>
19.00	<p>GALA DINNER ON THE TERRASSE PETIT PALAIS</p>		

Day 2 – Thursday 10th June 2010

08.30 – 09.00	Translational Medicine - Title to be Confirmed CONFIRMED: Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen		
	CONFERENCE ROOM 1: BIOMARKERS & PERSONALISED / TRANSLATIONAL MEDICINE	CONFERENCE ROOM 2: BIOINFORMATICS AND MODELLING	CONFERENCE ROOM 2: BIOLOGICS
	Stream Chair –	Stream Chair –	Stream Chair –
09.00 – 09.30	STREAM KEYNOTE PRESENTATION Title to be Confirmed RESERVED : Orest Hurko, Assistant Vice President Discovery Translational Research, Pfizer	STREAM KEYNOTE PRESENTATION Applied Systems Biology – Title to be Confirmed CONFIRMED: Birgit Schoeberl, Vice President of Discovery Merrimack Pharmaceuticals	STREAM KEYNOTE PRESENTATION Title to be Confirmed CONFIRMED: Jean-François Mayaux, Global Leader, Biotherapeutics & Protein Sciences, Sanofi Aventis
09.30 – 10.00	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk	Solution Provider Presentation For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk
10.00 – 12.20	MORNING REFRESHMENTS IN LA COUPOLE ONE TO ONE MEETINGS X 7 IN LEMAN A MEETING ROOM		
12.20 – 12.50	Title to be Confirmed CONFIRMED: Salvatore Alesci, Senior Director & Head, Translational Immunology, Pfizer	Computational Models to Predict Key Compound Quality Indicators – Title to be Confirmed CONFIRMED: Andy Davis, Associate Director, Physical & Metabolic Sciences, AstraZeneca	Antibodies as Therapeutics and Tools in Drug Discovery <ul style="list-style-type: none"> UCB's SLAM-based antibody technology platform provides both therapeutic candidates and tools for drug discovery. High affinity, function-modifying antibodies provide validation of targets, axes of intervention and specific binding sites. In addition, atomic contacts used by these antibodies can provide validated options for directed small molecule fragment growth. CONFIRMED: Alastair Lawson, Senior Director of Structural Biology, UCB

12.50 – 13.20	<p>Panel Discussion – The Utility of Biomarkers for PoC Decision Making and Patient Selection</p> <p>CONFIRMED: Hans Winkler, Senior Director, Global Head Oncology Biomarkers, Ortho Biotech Oncology R&D - Johnson & Johnson</p> <p>RESERVED : Orest Hurko, Assistant Vice President Discovery Translational Research, Pfizer</p> <p>Invitation to: Senior Representative x2</p>	<p>Panel Discussion – Free Tools for In Silico Screening and Successful Applications of Virtual Screening on Therapeutic Targets:</p> <p>CONFIRMED: Maria Miteva, Senior Scientist, Molécules Thérapeutiques In Silico (MTi) Université Paris</p> <p>Invitation to: Senior Representative x3</p>	<p>Panel Discussion – Biobetters</p> <ul style="list-style-type: none"> • Big-picture issues in discovery, development and regulatory affairs • Enhancing pharmacokinetics of antibodies • Novel production platforms for enhanced biosimilars • Technologies being exploited for Biobetters • Biobetters business model <p>CONFIRMED: John Desjarlais, Vice President, Research, Xencor Rob Hayes, CSO, CENTYREX a J&J Internal Venture Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson</p> <p>Invitation to: Senior Representative x1</p>
13.20 – 14.20	LUNCH ON THE TERRASSE PETIT PALAIS		
14.20 – 14.50	<p>Title to be Confirmed</p> <p>CONFIRMED: Jeffrey Waring, Associate Research Fellow, Senior Group Leader, Neuroscience Biomarker Discovery, Abbott</p>	<p>Title to be Confirmed</p> <p>CONFIRMED: John Overington, Team Leader, Chemogenomics, EMBL – European Bioinformatics Institute, EMBL-EBI</p>	<p>Pepducins – Novel Allosteric Modulators of GPCR Signalling</p> <ul style="list-style-type: none"> • Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. • Pepducins are comprised of a short peptide derived from the sequence of a GPCR intracellular loop linked to a hydrophobic moiety that anchor in membrane and modulate GPCR activity via a unique intracellular allosteric mechanism. • Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets and will be the focus of this presentation. <p>CONFIRMED: Stephen Hunt III, Senior Vice President, Discovery Research, Ascent Therapeutics</p>

14.50 – 15.20	<p>How Translational Experiments and Quantitative Knowledge Integration Facilitates Decision Making in Early Development</p> <p>CONFIRMED: Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, Head of Strategic Modeling and Simulation, Bristol Myers Squibb</p>	<p>Improving Probability of Success through Integrating <i>in vitro</i> ADME and <i>in vivo</i> PK data in Human PK predictions and PK/PD Modeling in Discovery.</p> <ul style="list-style-type: none"> • What key input data is needed and available for successful PK predictions using PBPK models at an early Discovery stage? • PK/PD modeling in early Discovery: nice-to-have or inevitable? <p>CONFIRMED: Marjoleen Nijsen, Head Preclinical PK/PD, Abbott GmbH & Co. KG, Germany</p>	<p>DNA-Programmed Chemistry Approaches to Macrocylic Lead Compounds</p> <ul style="list-style-type: none"> • Macrocycles provide drug-like compounds that are able to bind to difficult targets such as protein-protein interactions that are not readily addressed by 'Rule of 5'-compliant compounds • DNA-programmed chemistry is an integrated platform that allows the rapid synthesis of tens of thousands of macrocycles • Screening the libraries of macrocycles through affinity selection experiments rapidly reveals the identity of active compounds and their structure activity relationships <p>CONFIRMED: Nick Terrett, Chief Scientific Officer, Ensemble Discovery Corporation</p>
15.20 – 15.40	AFTERNOON REFRESHMENTS		
15.40 – 16.10	<p>Biomarkers Presentation - Title to be Confirmed</p> <p>RESERVED: Josef Ozer, Senior Principle Scientist, Pfizer</p>	<p>Knowledge Management and Data Integration Tools for the Drug Safety Sciences at Novartis</p> <ul style="list-style-type: none"> • Towards standard ontologies for pathology and anatomy for preclinical studies. • Tools developed for vocabulary integration into hierarchical ontologies. • Presenting Inspire - a knowledge management application for drug safety integrating 35 different data sources with impact across the Novartis organization • Why its time for open source and "insourcing" in the pharma industry. <p>CONFIRMED: David J. Heard, Group Head Bioinformatics in Investigative Toxicology, Preclinical Safety, Novartis Institutes for Biomedical Research</p>	<p>Design and Development of New Oligoclonal Anti-Tumor Antibodies</p> <ul style="list-style-type: none"> • Discussion of oligoclonal and polyclonal antibody therapeutics in human disease, including cancer • Discovery and development of Sym004 an anti-EGFR antibody pair with novel mechanisms of action and its implication for treatment of solid tumors • Future directions of rational design of oligoclonal anti-cancer antibodies <p>CONFIRMED: Søren Bregenholt, COO, Symphogen</p>
16.10 – 16.40	<p>Strategic Application of ADMET and PK/PD Modelling in Drug Discovery and Development</p> <p>RESERVED: Dennis Smith, Academic Research Fellow, Pfizer</p>	<p>Integration Not Isolation: The Role of Computational Systems Biology in the Design of Optimal Antibody Therapeutics</p> <ul style="list-style-type: none"> • Using model: • predict proliferation inhibition experiment • predict biomarker inhibition in whole blood • explain seeming contradiction in experiments - to develop MoA hypothesis • use model to optimize Ab characteristics in mechanistic PKPD simulations <p>CONFIRMED: John Burke, Associate Director, Systems Biology, Biotherapeutics and Integrative Biology, Boehringer Ingelheim Pharmaceuticals Inc</p>	<p>Advances in DARPins and Centyrins</p> <ul style="list-style-type: none"> • Advantages of alternative scaffold therapeutics • Applying the novel features of alternative scaffolds for protein therapeutics • Advances in the Centyrin scaffold <p>CONFIRMED: Karyn O'Neil , CSO, Johnson & Johnson Ventures</p>
16.40	CLOSE OF CONFERENCE		